p33ING1b methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions

He,Chun‑Gang; Huang,Qin‑Yuan; Chen,Li‑Sheng; Ling,Zhi‑An; Wu,Hong‑Gen; Deng,Hong‑Qiang

doi:10.3892/ol.2014.1923

p33ING1b methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions

Authors:
- Chun‑Gang He
- Qin‑Yuan Huang
- Li‑Sheng Chen
- Zhi‑An Ling
- Hong‑Gen Wu
- Hong‑Qiang Deng
View Affiliations

Affiliations: Department of General and Pediatric Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Nursing College of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: February 28, 2014 https://doi.org/10.3892/ol.2014.1923
Pages: 1639-1644

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the feasibility of detecting p33 inhibitor of growth 1b (p33ING1b) gene methylation in fecal DNA as a screening method for colorectal carcinoma (CRC) and precancerous lesions. The methylation of p33ING1b was analyzed in fecal samples from 61 patients with CRCs, 27 patients with precancerous lesions (advanced adenoma) and 20 normal individuals by nested methylation‑specific polymerase chain reaction (nMSP) and fecal occult blood test. Methylated p33ING1b was detected in 73.77% of CRC patients and 62.96% of adenoma patients. By contrast, only 5% of normal individuals had methylated p33ING1b. These results indicated 73.77% sensitivity for detecting CRC, 62.96% sensitivity for detecting precancerous lesions and 95% specificity of the assay for detecting CRCs and precancerous lesions. The detection of p33ING1b methylation status by incubation of DNA contained in agarose beads for bisulfite modification, followed by nMSP, is a promising non‑invasive screening method for CRCs and precancerous lesions.

View Figures

View References

1	Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2004. National Cancer Institute; Bethesda, MD: 2007, http://seer.cancer.gov/archive/csr/1975_2004/. Accessed April 6, 2009
2	Jenkinson F and Steele RJ: Colorectal cancer screening - methodology. Surgeon. 8:164–171. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mittag F, Kuester D, Vieth M, et al: DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett. 240:69–75. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lee BB, Lee EJ, Jung EH, et al: Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 15:6185–6191. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wang DR and Tang D: Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 14:524–531. 2008. View Article : Google Scholar
6	Pehlivan S, Artac M, Sever T, et al: Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 201:128–132. 2010. View Article : Google Scholar
7	Hellebrekers DM, Lentjes MH, van den Bosch SM, et al: GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 15:3990–3997. 2009. View Article : Google Scholar : PubMed/NCBI
8	Rojas A, Meherem S, Kim YH, et al: The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer. 123:14–21. 2008. View Article : Google Scholar : PubMed/NCBI
9	Liu W, Guan M, Su B, et al: Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: Application in colorectal cancer. Clin Chim Acta. 411:940–946. 2010. View Article : Google Scholar
10	Ying J, Li H, Yu J, et al: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar
11	Chen WD, Han ZJ, Skoletsky J, et al: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lenhard K, Bommer GT, Asutay S, et al: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 3:142–149. 2005. View Article : Google Scholar : PubMed/NCBI
13	Azuara D, Rodriguez-Moranta F, de Oca J, et al: Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin colorectal cancer. 9:168–176. 2010. View Article : Google Scholar : PubMed/NCBI
14	Petko Z, Ghiassi M, Shuber A, et al: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 11:1203–1209. 2005.PubMed/NCBI
15	Abbaszadegan MR, Tavasoli A, Velayati A, et al: Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol. 13:1528–1533. 2007. View Article : Google Scholar
16	Müller HM, Oberwalder M, Fiegl H, et al: Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 363:1283–1285. 2004.PubMed/NCBI
17	Grady WM, Rajput A, Lutterbaugh JD and Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61:900–902. 2001.PubMed/NCBI
18	Tallen G, Kaiser I, Krabbe S, et al: No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Int J Cancer. 109:476–479. 2004. View Article : Google Scholar
19	Nouman GS, Anderson JJ, Crosier S, et al: Downregulation of nuclear expression of the p33^ING1b inhibitor of growth protein in invasive carcinoma of the breast. J Clin Pathol. 56:507–511. 2003.PubMed/NCBI
20	Oki E, Maehara Y, Tokunaga E, et al: Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett. 147:157–162. 1999. View Article : Google Scholar : PubMed/NCBI
21	Chen L, Matsubara N, Yoshino T, et al: Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res. 61:4345–4349. 2001.
22	Shen DH, Chan KY, Khoo US, et al: Epigenetic and genetic alterations of p33^ING1b in ovarian cancer. Carcinogenesis. 26:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
23	Gunduz M, Ouchida M, Fukushima K, et al: Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 60:3143–3146. 2000.
24	Olek A, Oswald J and Walter J: A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 24:5064–5066. 1996. View Article : Google Scholar : PubMed/NCBI
25	Zhang Z, Sun D, Van do N, et al: Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer. 120:32–38. 2007. View Article : Google Scholar : PubMed/NCBI
26	Akobeng AK: Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 96:338–341. 2007. View Article : Google Scholar
27	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
28	Huang ZH, Li LH, Yang F and Wang JF: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 13:950–954. 2007. View Article : Google Scholar : PubMed/NCBI
29	Herman JG, Graff JR, Myöhänen S, et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Yang SB, Xie Y, et al: Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Cancer Epidemiol. 36:73–77. 2012. View Article : Google Scholar
31	Grunau C, Clark SJ and Rosenthal A: Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 29:e652001. View Article : Google Scholar
32	Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:5954–5958. 2000.
33	Mandel JS, Bond JH, Church TR, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med. 328:1365–1371. 1993. View Article : Google Scholar
34	Heresbach D, Manfredi S, D’Halluin PN, et al: Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 18:427–433. 2006. View Article : Google Scholar
35	Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 351:2704–2714. 2004. View Article : Google Scholar : PubMed/NCBI
36	Collins JF, Lieberman DA, Durbin TE, et al: Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 142:81–85. 2005. View Article : Google Scholar
37	Nadel MR, Shapiro JA, Klabunde CN, et al: A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med. 142:86–94. 2005.